Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels
- PMID: 26694878
- PMCID: PMC4851240
- DOI: 10.1002/sim.6848
Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels
Abstract
Consider a parallel group trial for the comparison of an experimental treatment to a control, where the second-stage sample size may depend on the blinded primary endpoint data as well as on additional blinded data from a secondary endpoint. For the setting of normally distributed endpoints, we demonstrate that this may lead to an inflation of the type I error rate if the null hypothesis holds for the primary but not the secondary endpoint. We derive upper bounds for the inflation of the type I error rate, both for trials that employ random allocation and for those that use block randomization. We illustrate the worst-case sample size reassessment rule in a case study. For both randomization strategies, the maximum type I error rate increases with the effect size in the secondary endpoint and the correlation between endpoints. The maximum inflation increases with smaller block sizes if information on the block size is used in the reassessment rule. Based on our findings, we do not question the well-established use of blinded sample size reassessment methods with nuisance parameter estimates computed from the blinded interim data of the primary endpoint. However, we demonstrate that the type I error rate control of these methods relies on the application of specific, binding, pre-planned and fully algorithmic sample size reassessment rules and does not extend to general or unplanned sample size adjustments based on blinded data. © 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.
Keywords: adaptive clinical trials; blinded interim analysis; block randomization; random allocation; sample size reassessment; type I error rate control.
© 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.
Figures



Similar articles
-
Estimation after blinded sample size reassessment.Stat Methods Med Res. 2018 Jun;27(6):1830-1846. doi: 10.1177/0962280216670424. Epub 2016 Oct 2. Stat Methods Med Res. 2018. PMID: 27697838 Free PMC article.
-
Blinded continuous monitoring in clinical trials with recurrent event endpoints.Pharm Stat. 2019 Jan;18(1):54-64. doi: 10.1002/pst.1907. Epub 2018 Oct 21. Pharm Stat. 2019. PMID: 30345693 Free PMC article.
-
Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications.Biom J. 2014 Jul;56(4):614-30. doi: 10.1002/bimj.201300153. Epub 2014 Apr 22. Biom J. 2014. PMID: 24753160 Free PMC article.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Review of Acute Treatment of Migraine Trial Results With the New FDA Endpoints: Design Implications for Future Trials.Headache. 2019 May;59(5):819-824. doi: 10.1111/head.13511. Epub 2019 Apr 6. Headache. 2019. PMID: 30953576 Free PMC article. Review.
Cited by
-
Estimation after blinded sample size reassessment.Stat Methods Med Res. 2018 Jun;27(6):1830-1846. doi: 10.1177/0962280216670424. Epub 2016 Oct 2. Stat Methods Med Res. 2018. PMID: 27697838 Free PMC article.
-
Preventing Respiratory Viral Illness Invisibly (PRiVII): protocol for a pragmatic cluster randomized trial evaluating far-UVC light devices in long-term care facilities to reduce infections.Trials. 2024 Jan 26;25(1):88. doi: 10.1186/s13063-024-07909-0. Trials. 2024. PMID: 38279184 Free PMC article.
-
Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.Trials. 2018 Nov 20;19(1):642. doi: 10.1186/s13063-018-3012-x. Trials. 2018. PMID: 30454061 Free PMC article.
-
Phytocannabinoids for the Treatment of Neuropathic Pain: A Scoping Review of Randomised Controlled Trials Published Between 2012 and 2023.Curr Pain Headache Rep. 2024 Mar;28(3):109-118. doi: 10.1007/s11916-023-01196-1. Epub 2023 Dec 14. Curr Pain Headache Rep. 2024. PMID: 38095748
-
Improving the Effectiveness of Sample Size Re-Estimation: An Operating Characteristic Focused, Hybrid Frequentist-Bayesian Approach.Stat Med. 2025 Feb 10;44(3-4):e10310. doi: 10.1002/sim.10310. Stat Med. 2025. PMID: 39865327 Free PMC article.
References
-
- ICH Topic E9: Notes for guidance on statistical principles for clinical trials, European Agency for the Evaluation of Medical Products: London, UK, 1998.
-
- Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics. 1995; 51: 1315–1324. - PubMed
-
- Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics. 1994; 50: 1029–1041. - PubMed
-
- Posch M, Bauer P, Brannath W. Issues in designing flexible trials. Statistics in Medicine. 2003; 23: 953–969. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources